| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Common Stock | Options Exercise | $2,589,310 | +85,824 | +58% | $30.17 | 232,775 | 22 Feb 2025 | Direct | F1 |
| transaction | PFE | Common Stock | Tax liability | $87,684 | -3,334 | -1.4% | $26.30 | 229,441 | 22 Feb 2025 | Direct | F2, F3 |
| transaction | PFE | Common Stock | Tax liability | $1,996,815 | -76,565 | -33% | $26.08 | 152,876 | 22 Feb 2025 | Direct | F4, F5 |
| holding | PFE | Common Stock | 1,951 | 22 Feb 2025 | By Rule 16b-3 Plan |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Stock Appreciation Rights | Options Exercise | $0 | -85,824 | -100% | $0.000000 | 0 | 22 Feb 2025 | Common Stock | 85,824 | $30.17 | Direct |
| Id | Content |
|---|---|
| F1 | The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). |
| F2 | The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. |
| F3 | Price is the closing price of Pfizer common stock on February 21, 2025. |
| F4 | The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). |
| F5 | Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |
dlxpoa24.htm